CME Presentations

GvHD and its Impact on Patients



  • Zachariah DeFilipp, MD

    Zachariah DeFilipp, MD

    Zachariah DeFilipp, MD

    Director of BMT Clinical Research

    Zachariah DeFilipp, MD, is an attending physician in the Hematopoietic Cell Transplant and Cell Therapy Program at the Massachusetts General Hospital Cancer Center. He serves as Director of BMT Clinical Research and an Assistant Professor in Medicine at Harvard Medical School. Dr. DeFilipp is involved in translational and clinical research initiatives to improve outcomes for patients undergoing allogeneic hematopoietic cell transplantation. His research is on the development of approaches to the prevention and treatment of graft-versus-host disease. Also, his research efforts have explored improving transplant outcomes for high-risk leukemia through the incorporation of targeted agents in pre- and post-transplant and examining late effects following amongst long-term transplant survivors.

CME Information

Global Logo PQH Logo
Tackling Chronic GvHD: Patient‐centered Approaches
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD).


This activity is supported by an independent educational grant from Incyte Corporation.


This activity was released on January 16, 2024 and is valid for 12 months. Requests for credit must be made no later than January 16, 2025.


The educational design of this activity addresses the needs of community‐based and academic hematologic oncologists, hematologists, medical oncologists, pathologists, transplant specialists, oncology nurses and nurse navigators. Secondarily, addresses the needs of primary care providers, nurse practitioners, physician assistants, and pharmacists.


Despite the approval of new therapeutic agents and ongoing research in chronic graft-versus-host disease (GvHD), patients still experience significant disease burden. Education on the symptom constellation, multidisciplinary approaches to improving patients’ quality of life, safety and efficacy of approved and emerging agents, treatment selection, and side‐effect management can help close identified knowledge and practice gaps among clinicians who provide care for patients with chronic GvHD.

Join Zachariah DeFilipp, MD to discuss therapeutic approaches to the management of chronic GvHD, along with effective strategies to improve patient outcomes.


After completing this activity, the participant should be better able to:
  • Review strategies to improve quality of life for patients with chronic GvHD
  • Incorporate evidence-based approaches (current and emerging) into the management of chronic GvHD


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 30 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Zachariah DeFilipp, MD
Director of BMT Clinical Research
Assistant Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Consulting Fee (e.g., Advisory Board): Sanofi, Incyte, Corp., MorphoSys AG, Inhibrx, PharmaBiome AG, and Ono Pharmaceutical
Contracted Research (Principal Investigators must provide information, even if received by the institution): Incyte, Corp., Regimmune, Corp., and Taiho Oncology, Inc.

The planners and managers at Global Education Group have no relevant financial relationships to disclose. 

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Physician Accreditation Support:

For information about the physician accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at